| Lapatinib plus capecitabine for HER2-positive advanced breast cancer CE Geyer, J Forster, D Lindquist, S Chan, CG Romieu, T Pienkowski, ... New England journal of medicine 355 (26), 2733-2743, 2006 | 4063 | 2006 |
| Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, ... New England Journal of Medicine 366 (6), 520-529, 2012 | 3230 | 2012 |
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ... New England journal of medicine 372 (8), 724-734, 2015 | 2080 | 2015 |
| Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ... New England Journal of Medicine 380 (20), 1929-1940, 2019 | 1719 | 2019 |
| Ribociclib as first-line therapy for HR-positive, advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... New England journal of medicine 375 (18), 1738-1748, 2016 | 1623 | 2016 |
| MONARCH 3: abemaciclib as initial therapy for advanced breast cancer MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ... J clin oncol 35 (32), 3638-3646, 2017 | 1269 | 2017 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo … SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov, M Campone, E Ciruelos, ... The lancet oncology 14 (6), 461-471, 2013 | 1079 | 2013 |
| A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated … D Cameron, M Casey, M Press, D Lindquist, T Pienkowski, CG Romieu, ... Breast cancer research and treatment 112, 533-543, 2008 | 1063 | 2008 |
| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept … C Le Tourneau, JP Delord, A Gonçalves, C Gavoille, C Dubot, N Isambert, ... The lancet oncology 16 (13), 1324-1334, 2015 | 998 | 2015 |
| Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer J Baselga, V Semiglazov, P van Dam, A Manikhas, M Bellet, ... Journal of Clinical Oncology 27 (16), 2630-2637, 2009 | 794 | 2009 |
| Lomustine and bevacizumab in progressive glioblastoma W Wick, T Gorlia, M Bendszus, M Taphoorn, F Sahm, I Harting, ... New England Journal of Medicine 377 (20), 1954-1963, 2017 | 780 | 2017 |
| Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial H Roché, P Fumoleau, M Spielmann, JL Canon, T Delozier, D Serin, ... Journal of Clinical Oncology 24 (36), 5664-5671, 2006 | 762 | 2006 |
| Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study T Bachelot, G Romieu, M Campone, V Diéras, C Cropet, F Dalenc, ... The lancet oncology 14 (1), 64-71, 2013 | 741 | 2013 |
| A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer P Farmer, H Bonnefoi, P Anderle, D Cameron, P Wirapati, V Becette, ... Nature medicine 15 (1), 68-74, 2009 | 708 | 2009 |
| Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment ES Thomas, HL Gomez, RK Li, HC Chung, LE Fein, VF Chan, J Jassem, ... Journal of Clinical Oncology 26 (13), 2223-2223, 2008 | 649 | 2008 |
| Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced … GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... Annals of Oncology 29 (7), 1541-1547, 2018 | 620 | 2018 |
| Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 MJ van den Bent, AA Brandes, R Rampling, MCM Kouwenhoven, JM Kros, ... Journal of Clinical Oncology 27 (8), 1268, 2009 | 604 | 2009 |
| Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 M Piccart, GN Hortobagyi, M Campone, KI Pritchard, F Lebrun, Y Ito, ... Annals of oncology 25 (12), 2357-2362, 2014 | 577 | 2014 |
| Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis DA Yardley, S Noguchi, KI Pritchard, HA Burris, J Baselga, M Gnant, ... Advances in therapy 30, 870-884, 2013 | 558 | 2013 |
| Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma TT Batchelor, P Mulholland, B Neyns, LB Nabors, M Campone, A Wick, ... Journal of Clinical Oncology 31 (26), 3212, 2013 | 545 | 2013 |
